BankPlus Trust Department Has $1.25 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

BankPlus Trust Department lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1,386.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,962 shares of the company’s stock after purchasing an additional 1,830 shares during the period. BankPlus Trust Department’s holdings in IDEXX Laboratories were worth $1,254,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. Opal Wealth Advisors LLC acquired a new position in IDEXX Laboratories during the second quarter worth $29,000. WealthCollab LLC acquired a new position in shares of IDEXX Laboratories during the 2nd quarter worth about $30,000. Armstrong Advisory Group Inc. increased its stake in shares of IDEXX Laboratories by 55.9% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after purchasing an additional 19 shares during the last quarter. Ameritas Advisory Services LLC bought a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at about $36,000. Finally, Elevation Point Wealth Partners LLC acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at about $36,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the sale, the executive vice president directly owned 21,149 shares in the company, valued at approximately $14,874,937.66. This represents a 30.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $688.48 on Friday. The firm has a 50-day moving average price of $695.70 and a two-hundred day moving average price of $632.09. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98. The company has a market capitalization of $54.98 billion, a P/E ratio of 54.60, a P/E/G ratio of 4.11 and a beta of 1.67. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The firm’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. JPMorgan Chase & Co. boosted their price target on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. UBS Group lifted their target price on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 4th. Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, December 22nd. Leerink Partners set a $785.00 price target on IDEXX Laboratories in a report on Monday, November 3rd. Finally, Morgan Stanley upped their price objective on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $763.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.